Brevicillin®: The Probiotic That Makes (Intrinsic) Antibiotic Resistance Beneficial

Antibiotics, though essential in combating bacterial infections, often disrupt gut microbiota, leaving patients vulnerable to gastrointestinal complications.

The introduction of Brevicillin®—a probiotic based on Bifidobacterium breve PRL2020 with intrinsic resistance to amoxicillin and amoxicillin-clavulanate—marks a pivotal step in safeguarding gut health during antibiotic therapy.

Intrinsic Resistance: A Game-Changer in Probiotic Technology

Traditional probiotics struggle to survive when co-administered with antibiotics, as most beneficial bacterial strains are equally susceptible to these drugs. Brevicillin®, however, leverages Bifidobacterium breve PRL2020, an innovative probiotic strain whose intrinsic resistance to amoxicillin and amoxicillin-clavulanate ensures its viability even in the presence of these antibiotics.

This unique feature enables Brevicillin® to persist in the gut microbiota during therapy and allows it to provide continuous support in preserving the intestinal barrier. Furthermore, it actively counters the proliferation of potential pathogens that could otherwise exploit the ecological niche left vacant by bifidobacteria, which are typically compromised during amoxicillin/clavulanic acid therapy.

Intrinsic Resistance: Its Safety profile in Brevicillin®

Intrinsic resistance refers to the naturally occurring ability of specific probiotic strains to withstand the action of certain antibiotics. Unlike acquired resistance, which can spread between bacteria and contribute to the global issue of antimicrobial resistance, intrinsic resistance is a stable, non-transferable trait.

In the case of Brevicillin®, this resistance is:

  • Specific: It is limited to amoxicillin and amoxicillin-clavulanate, ensuring compatibility with these commonly prescribed antibiotics without interfering with the broader microbial ecosystem.
  • Non-Transferable: The resistance mechanism is embedded within the genetic makeup of the probiotic strain, making it impossible for pathogenic bacteria in the gut to acquire this trait.
  • Scientifically validated: Rigorous research, including the strain’s full genome sequencing and its inclusion in the EFSA QPS (Qualified Presumption of Safety) list, confirms Brevicillin®’s safety profile and preserves its therapeutic value.


This safety assurance makes Brevicillin® an ideal partner in antibiotic therapy, addressing an unmet need for probiotics that can effectively coexist with antibiotics without unintended consequences.

Clinical Relevance: Why Brevicillin® Stands Out

  1. Protection of Intestinal Microbiota: The Bifidobacterium breve PRL2020 strain in Brevicillin® withstands the effects of antibiotics, maintaining its beneficial activity in the gut and continuing to support essential microbiota functions during therapy.
  2. Reduction in Dysbiosis Risk: Brevicillin® actively helps preserve microbial diversity, minimizing disruptions to the gut ecosystem and reducing side effects such as diarrhea, bloating, or intestinal discomfort often associated with antibiotic treatments.
  3. Prevention of Opportunistic Pathogen Overgrowth: By safeguarding intestinal balance, Brevicillin® prevents the proliferation of pathogenic microorganisms that could otherwise exploit microbiota disruptions, reducing the risk of secondary infections.
  4. Enhanced Post-Therapy Recovery: By ensuring greater stability of the gut microbiota during antibiotic therapy, Brevicillin® supports faster and more complete restoration of intestinal flora once treatment concludes.

Brevicillin®: Beyond a Probiotic

What truly differentiates Brevicillin® is its role as a proactive therapeutic tool. It doesn’t merely accompany antibiotic therapy—it actively bridges the gap between necessary antibiotic treatment and the need for sustained gut health. By reducing the collateral damage of antibiotics on beneficial gut microbiota, Brevicillin® aligns with the growing demand for integrative healthcare solutions that prioritize both efficacy and safety.

Brevicillin®’s innovative mechanism of action equips healthcare professionals with a reliable probiotic partner to combat one of the most common side effects of antibiotic use. By prioritizing intrinsic resistance to specific antibiotics, it offers an advanced, scientifically backed solution for protecting and nurturing gut health, representing a step toward harmonizing effective antibiotic therapy with microbiota preservation.

To learn more about Brevicillin®, we invite you to visit the website www.brevicillin.it/en.